Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Jan 18;3(1):100506.
doi: 10.1016/j.xcrm.2021.100506.

MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

B Leticia Rodriguez  1 , Don L Gibbons  1   2
Affiliations
Comment

MEK inhibition invigorates chemoimmunotherapy by tumor mitophagy-induced CXCL10 expression

B Leticia Rodriguez et al. Cell Rep Med. .

Abstract

A recent study by Limagne et al.1 in Cancer Cell demonstrates that addition of MEK inhibitor to standard-of-care platinum/pemetrexed promotes mitophagy-dependent CXCL10 expression via optineurin and TLR9. Tumor cell secretion of CXCL10 produces T cell recruitment and enhances immunotherapy efficacy.

PubMed Disclaimer

Conflict of interest statement

D.L.G. has received research funding from AstraZeneca, Astellas, Janssen, Ribon Therapeutics, Takeda, and NGM Biopharmaceuticals; reports advisory role/consulting fees from AstraZeneca, Sanofi, Menarini Ricerche, and Eli Lilly; and research funding to MD Anderson Cancer Center from Boehringer Ingelheim. B.L.R. declares no competing interests.

Comment on

  • MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.
    Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F. Limagne E, et al. Cancer Cell. 2022 Feb 14;40(2):136-152.e12. doi: 10.1016/j.ccell.2021.12.009. Epub 2022 Jan 19. Cancer Cell. 2022. PMID: 35051357

References

    1. Limagne E., Nuttin L., Thibaudin M., Jacquin E., Aucagne R., Bon M., Revy S., Barnestein R., Ballot E., Truntzer C., et al. MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells. Cancer Cell. 2021 doi: 10.1016/j.ccell.2021.12.009. Published January 13, 2022. - DOI - PubMed
    1. Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., De Angelis F., Domine M., Clingan P., Hochmair M.J., Powell S.F., et al. KEYNOTE-189 Investigators Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N. Engl. J. Med. 2018;378:2078–2092. doi: 10.1056/NEJMoa1801005. - DOI - PubMed
    1. Peng D.H., Rodriguez B.L., Diao L., Gaudreau P.O., Padhye A., Konen J.M., Ochieng J.K., Class C.A., Fradette J.J., Gibson L., et al. Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. Nat. Commun. 2021;12:2606. doi: 10.1038/s41467-021-22875-w. - DOI - PMC - PubMed
    1. Wang Y., Liu S., Yang Z., Algazi A.P., Lomeli S.H., Wang Y., Othus M., Hong A., Wang X., Randolph C.E., et al. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 2021;39:1375–1387.e6. doi: 10.1016/j.ccell.2021.07.023. - DOI - PMC - PubMed
    1. Haas L., Elewaut A., Gerard C.L., Umkehrer C., Leiendecker L., Pedersen M., Krecioch I., Hoffmann D., Novatchkova M., Kuttke M., et al. Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nat. Can. 2021;2:693–708. doi: 10.1038/s43018-021-00221-9. - DOI - PMC - PubMed

Substances